Evotec SE Asset Resilience Ratio
Evotec SE asset resilience ratio. Evotec SE (EVT) has an Asset Resilience Ratio of 7.45% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See EVT defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Evotec SE (2003–2025)
Asset resilience ratio of Evotec SE from 2003 to 2025. This chart shows how Evotec SE's Asset Resilience Ratio has changed over time. Read Evotec SE debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Evotec SE's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Evotec SE asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €117.23 Million | 7.45% |
| Total Liquid Assets | €117.23 Million | 7.45% |
Asset Resilience Insights
- Limited Liquidity: Evotec SE maintains only 7.45% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Evotec SE Industry Peers by Asset Resilience Ratio
Compare Evotec SE's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE |
Drug Manufacturers - Specialty & Generic | 1.38% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Cansino Biologics Inc
SHG:688185 |
Drug Manufacturers - Specialty & Generic | 19.62% |
Evotec SE Asset Resilience Ratio by Year (2003–2025)
Evotec SE asset resilience ratio by year from 2003 to 2025. The table below shows the annual Asset Resilience Ratio data for Evotec SE.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 26.78% | €476.39 Million ≈ $556.95 Million |
€1.78 Billion ≈ $2.08 Billion |
+6.03pp |
| 2024-12-31 | 20.75% | €396.80 Million ≈ $463.90 Million |
€1.91 Billion ≈ $2.24 Billion |
-6.07pp |
| 2023-12-31 | 26.82% | €604.11 Million ≈ $706.27 Million |
€2.25 Billion ≈ $2.63 Billion |
-5.52pp |
| 2022-12-31 | 32.34% | €729.98 Million ≈ $853.43 Million |
€2.26 Billion ≈ $2.64 Billion |
-6.07pp |
| 2021-12-31 | 38.41% | €858.50 Million ≈ $1.00 Billion |
€2.24 Billion ≈ $2.61 Billion |
+4.73pp |
| 2020-12-31 | 33.68% | €492.63 Million ≈ $575.94 Million |
€1.46 Billion ≈ $1.71 Billion |
+6.44pp |
| 2019-12-31 | 27.24% | €321.66 Million ≈ $376.06 Million |
€1.18 Billion ≈ $1.38 Billion |
+7.82pp |
| 2018-12-31 | 19.42% | €149.88 Million ≈ $175.22 Million |
€771.88 Million ≈ $902.41 Million |
+4.19pp |
| 2017-12-31 | 15.22% | €101.58 Million ≈ $118.75 Million |
€667.27 Million ≈ $780.11 Million |
-21.17pp |
| 2016-12-31 | 36.39% | €127.86 Million ≈ $149.48 Million |
€351.37 Million ≈ $410.78 Million |
+5.04pp |
| 2015-12-31 | 31.35% | €90.46 Million ≈ $105.76 Million |
€288.54 Million ≈ $337.33 Million |
+13.01pp |
| 2014-12-31 | 18.35% | €41.21 Million ≈ $48.17 Million |
€224.60 Million ≈ $262.58 Million |
-4.74pp |
| 2013-12-31 | 23.09% | €52.49 Million ≈ $61.37 Million |
€227.38 Million ≈ $265.83 Million |
+11.30pp |
| 2012-12-31 | 11.79% | €26.57 Million ≈ $31.07 Million |
€225.43 Million ≈ $263.55 Million |
-9.30pp |
| 2011-12-31 | 21.08% | €46.01 Million ≈ $53.79 Million |
€218.21 Million ≈ $255.11 Million |
-3.65pp |
| 2010-12-31 | 24.73% | €47.45 Million ≈ $55.47 Million |
€191.86 Million ≈ $224.30 Million |
+7.38pp |
| 2009-12-31 | 17.35% | €25.43 Million ≈ $29.73 Million |
€146.60 Million ≈ $171.39 Million |
+1.47pp |
| 2008-12-31 | 15.87% | €29.03 Million ≈ $33.94 Million |
€182.90 Million ≈ $213.83 Million |
-12.09pp |
| 2007-12-31 | 27.97% | €58.14 Million ≈ $67.97 Million |
€207.88 Million ≈ $243.03 Million |
+17.98pp |
| 2006-12-31 | 9.99% | €20.53 Million ≈ $24.00 Million |
€205.53 Million ≈ $240.28 Million |
-40.25pp |
| 2005-12-31 | 50.24% | €93.50 Million ≈ $109.31 Million |
€186.11 Million ≈ $217.58 Million |
-34.42pp |
| 2004-12-31 | 84.66% | €60.03 Million ≈ $70.18 Million |
€70.91 Million ≈ $82.90 Million |
+9.14pp |
| 2003-12-31 | 75.52% | €31.51 Million ≈ $36.84 Million |
€41.73 Million ≈ $48.78 Million |
-- |
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more